



UNITED STATES PATENT AND TRADEMARK OFFICE

EA

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/510,014	04/11/2005	Amanda Proudfoot	ARS-103	4504
23557	7590	05/15/2006	EXAMINER	
SALIWANCHIK LLOYD & SALIWANCHIK A PROFESSIONAL ASSOCIATION PO BOX 142950 GAINESVILLE, FL 32614-2950			HISSONG, BRUCE D	
			ART UNIT	PAPER NUMBER
			1646	

DATE MAILED: 05/15/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO. <i>10/510,014</i>	FILING DATE <i>04/11/2005</i>	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION <i>Amanda Proudfoot</i>	ATTORNEY DOCKET NO. <i>ARS-103</i>
--	----------------------------------	--	---------------------------------------

EXAMINER

Bruce D. Hissang

ART UNIT	PAPER
----------	-------

1646

050906

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The amendment filed on 2/21/2006 canceling all claims drawn to the elected invention and presenting only claims drawn to a non-elected invention is non-responsive (MPEP § 821.03). The remaining claims are not readable on the elected invention because claims 6-12, which were examined in the Office Action mailed on 11/3/2005, were drawn to an isolated polypeptide comprising SEQ ID NO: 1 and a method of administering said polypeptide, as elected in a telephone call with Dr. Frank C. Eisenschenk on 8/11/2005. The amendment filed on 2/21/2006 presents claims that are drawn to methods of treating autoimmune and/or inflammatory diseases and/or bacterial and viral infections. Because the claims are drawn to methods of treating a disease, and not drawn to an isolated polypeptide comprising SEQ ID NO: 1, the newly submitted claims are drawn to non-elected subject matter.

Since the above-mentioned amendment appears to be a *bona fide* attempt to reply, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS, whichever is longer, from the mailing date of this notice within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD UNDER 37 CFR 1.136(a) ARE AVAILABLE.

BDH
Art Unit 1646

Robert S. Landsman
ROBERT S. LANDSMAN, PH.D.
PRIMARY EXAMINER